• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Enzalutamide reduces risk of metastatic prostate cancer in at-risk men

byDayton McMillan
July 3, 2018
in Chronic Disease, Endocrinology, Oncology, Surgery, Urology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Prostate cancer patients with a rapidly risking prostate-specific antigen (PSA) despite chemical or physical castration had lower rates of metastasis when treated with enzalutamide compared to those in a placebo group.

2. No difference in overall survival was observed between the treatment and placebo groups at a median follow-up time of 18.4 and 11.1 months for the two groups, respectively.

Evidence Rating Level: 1 (Excellent)     

Study Rundown: Prostate cancer is associated with metastasis, and rapidly rising PSA and castration-resistant subtypes of prostate cancer are significant metastatic risk factors. For men considered at-risk for metastasis hormonal therapy is used to prolong metastasis-free (MFS) and overall (OS) survival, though clinical evidence supporting some of these methods are limited. Enzalutamide binds to the androgen receptor and inhibits downstream androgen effects. Previous work has shown enzalutamide treatment can increase both progression-free (PFS) and OS. The PROSPER trial sought to assess effect of enzalutamide on MFS in patients with castration-resistance and rapidly rising PSA. Median MFS was significantly greater in patients treated with enzalutamide compared to placebo, and time until subsequent antineoplastic therapy was also significantly longer in the treatment group.

Strengths of this study include thorough reporting of adverse outcomes and international, multi-institutional design. Limitations include lack of reporting on treatments the patients may have undergone, including radiation and/or surgeries.

Click to read the study, published in NEJM

RELATED REPORTS

Exercise improves sexual function in men with prostate cancer  

Genome classifiers may aid prostate cancer risk stratification and treatment

Radiotherapy and abiraterone improve survival in low-volume metastatic castration-sensitive prostate cancer

Relevant Reading: The evolutionary history of lethal metastatic prostate cancer

In-Depth [randomized controlled trial]: This double-blind, phase 3 randomized controlled trial enrolled patients between 2013 and 2017. Eligible patients had prostate adenocarcinoma with rising PSA (doubling time of less than 10 months) despite testosterone levels consistent with castration as all patients either had a bilateral orchiectomy or had been receiving androgen deprivation therapy. Patients had no metastatic disease as confirmed by CT or MRI, and whole-body radionuclide scanning. Patients were randomized into enzalutamide (n = 933) and placebo (n = 468) groups. Evaluation for metastasis by radiographic imaging was performed every 16 weeks during follow-up. The primary endpoint was MFS starting from randomization and key secondary endpoints included PSA progression and OS.

At a median duration of trial follow-up of 18.4 months in the treatment group and 11.1 months in the placebo group, median MFS was 36.6 months in the treatment group and 14.7 months in the placebo group. Enzalutamide was associated with a 71% lower risk of metastasis than placebo (hazard ratio [HR], 0.29; 95% confidence interval [CI], 0.24 to 0.35; p < 0.001). PSA progression occurred in 69% of the placebo group and 22% of the control group (p < 0.001). There was no significant difference in overall survival between the treatment (11%) and placebo (13%) groups (p = 0.15). Enzalutamide treated patients used subsequent antineoplastic therapy at a lower rate than placebo patients (15% vs 48%, p < 0.001).

Image: CC/Wiki

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: enzalutamideprostate cancer
Previous Post

Dupilumab reduces systemic glucocorticoid use in severe asthmatics

Next Post

Family-support intervention does not significantly improve surrogates’ psychological symptoms: The PARTNER trial

RelatedReports

Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial
Chronic Disease

Exercise improves sexual function in men with prostate cancer  

May 24, 2025
BRAF V600E mutations linked with increased mortality in thyroid cancer
Oncology

Genome classifiers may aid prostate cancer risk stratification and treatment

January 20, 2025
Androgen deprivation in prostate cancer: intermittent may compromise survival
Chronic Disease

Radiotherapy and abiraterone improve survival in low-volume metastatic castration-sensitive prostate cancer

December 18, 2024
Sunitinib showed no change in overall survival for metastatic prostate cancer
Chronic Disease

Stereotactic body radiotherapy is noninferior to hypofractionated radiotherapy for localized prostate cancer

November 22, 2024
Next Post

Family-support intervention does not significantly improve surrogates’ psychological symptoms: The PARTNER trial

Maternal vaccination during pregnancy not associated with infant hospitalization, mortality

Women who experience hypertensive disorders during pregnancy are at high risk for developing high blood pressure, diabetes, and high cholesterol later in life

Parental cannabis use increasing, cigarette use decreasing

Regular marijuana use is associated with development of respiratory issues

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Tirzepatide-associated improvements in cardiometabolic risk factors linked to degree of weight loss
  • Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
  • 2 Minute Medicine Rewind June 23, 2025
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.